Lung repair cells tested in fibrosis trial

NCT ID NCT06081621

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study tested a cell therapy called REGEND001 for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. 23 adults received either the cell treatment or a placebo to see if it could improve lung function. The therapy uses special lung cells that may help repair damaged tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Renji Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, 200127, China

  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, 361021, China

Conditions

Explore the condition pages connected to this study.